Answers are grounded in this paper and cite their sources.
Introduction: To evaluate the experience of families of children (aged 7-14) with type 1 diabetes participating in a model of diabetes care that utilises regular remote review of CGM to prioritise contact and provide personalised and targeted support. This study focused on exploring the acceptability and impact of this model of care on participants and their families. Methods: This mixed-methods study used semi-structured interviews and a combined multiple-choice and free-text survey, completed by parents of children participating in a trial model of diabetes care. Qualitative data was analysed via reflexive content analysis to establish categories describing the experience and acceptability of the model of care. Quantitative data reflecting acceptability of the model of care were reported using frequency of response. Results: A sample of 15 surveys and 9 interviews were completed from 59 eligible participants who completed the model of care. The primary outcome, family experience of receiving contact, was most frequently referenced with 83% reporting positive personal impacts such as reassurance, support and validation, 46% reporting improved wellbeing and 70% reporting impacts on diabetes self-knowledge and management changes. Secondarily, the model was largely seen to be acceptable with 83% reporting convenient, positive and flexible communication and with potential to add-value to and reduce the requirement of traditional outpatient clinical care. Further, most participants reported a desire to continue the model of care. Participants also described potential revisions to improve the model and target specific populations who may benefit. Conclusions: This study suggested acceptability and subjective benefit of regular review of CGM by the clinical team with targeted remote intervention in a group of children with T1D. It highlights the value that families place on support and communication, independent of glycaemic benefits. This insight may be used to guide clinical contacts and future trials
No takes yet. Share an insight, caveat, or question.
Gehrmann et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: